brigatinib
Drug Details
- Generic Name
- brigatinib
- Brand Names
- Alunbrig
- Application Number
- NDA208772
- Sponsor
- Takeda Pharmaceuticals America, Inc.
- NDC Codes
- 5
- Dosage Forms
- TABLET, FILM COATED, POWDER, KIT
- Routes
- ORAL
- Active Ingredients
- BRIGATINIB
Indications and Usage
1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )